What is the current market size?

The Advanced Therapy Based on Gene market size was valued at USD 1.2 billion in 2023, driven by increasing approvals for gene therapies in oncology and rare diseases.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advancements in CRISPR and rising investments in biotech R&D.

What are the key growth drivers?

Key drivers include growing demand for precision medicine, expanding applications in oncology, and government funding for genetic research.

What challenges does the market face?

High development costs, stringent regulatory requirements, and manufacturing scalability issues hinder market growth.

Which regions are leading the market?

North America dominates the market, followed by Europe, while Asia-Pacific is emerging as a high-growth region due to improving healthcare infrastructure.

Who are the top companies in the market?

Leading players include Novartis, GSK, CRISPR Therapeutics, and bluebird bio, focusing on innovative product pipelines and strategic partnerships.

What are the future opportunities?

Opportunities lie in expanding therapies for autoimmune diseases, leveraging AI for gene targeting, and exploring cell-based gene therapy combinations.

How is technology impacting the market?

Advances in gene-editing tools like CRISPR and synthetic biology are accelerating clinical trial success rates and reducing development timelines.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA are streamlining approvals for gene therapies while emphasizing long-term safety monitoring and data transparency.

Advanced Therapy Based on Gene Market Intelligence Report 2026 — Updated June 2026

Advanced Therapy Based on Gene by Type (/> Viral, Non-viral), by Application (/> Neurological Diseases, Cancer, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Advanced Therapy Based on Gene Market Overview

The Advanced Therapy Based on Gene market encompasses innovative treatments leveraging gene therapy to address genetic disorders, oncological diseases, and chronic illnesses. With a projected Advanced Therapy Based on Gene market size of USD 2.5 billion in 2026, this sector is poised for transformative industry expansion, driven by breakthroughs in CRISPR, lentiviral vectors, and personalized medicine. The growth outlook underscores a compound annual growth rate (CAGR) exceeding 23.4% through 2033, reflecting macroeconomic tailwinds from aging populations and rising rare disease diagnostics.

Loading chart…

Key market forecast drivers include 1). technological maturation in gene-editing precision, 2). regulatory tailwinds from FDA/EMA approvals, and 3). cross-sector partnerships accelerating commercialization. North America dominates with 52% of 2026 revenues, while Asia-Pacific, spurred by government-funded biotech hubs in Japan and China, is forecast to grow at the highest CAGR (28.1%) through 2033. Strategic acquisitions and next-gen adeno-associated virus (AAV) vector innovations will define competitive intensity in this high-stakes, R&D-intensive sector.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	8.17 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rapid advancements in CRISPR-Cas9 and viral vector technologies are accelerating the development of Advanced Therapy Based on Gene market products, enabling more precise and scalable gene-editing solutions. These innovations are expected to drive the market size toward a growth forecast of 25% CAGR through 2030.

Increasing global investments in rare disease research, supported by public-private partnerships and regulatory incentives such as FDA’s Orphan Drug Act, are fueling clinical trial pipelines. This demand is further amplified by rising patient awareness and reimbursement expansions in developed markets.

Restraints2 items

High manufacturing costs and scalability limitations in viral vector production remain critical bottlenecks, particularly for autologous therapies. These challenges constrain market accessibility and delay commercialization timelines for Advanced Therapy Based on Gene market players.

Stringent regulatory scrutiny and evolving guidelines for long-term safety monitoring create compliance complexities. Delays in approvals due to data gaps in post-market surveillance hinder rapid market expansion, especially in emerging economies.

Opportunities2 items

Expanding applications beyond monogenic diseases into oncology, neurodegenerative disorders, and infectious diseases open new revenue streams. The Advanced Therapy Based on Gene market is poised to leverage these indications to diversify its growth forecast.

Strategic collaborations between biotech firms and contract development organizations (CDMOs) are addressing manufacturing gaps. These partnerships are critical for scaling production to meet the projected Advanced Therapy Based on Gene market size expansion in the next decade.

Challenges2 items

Ethical and societal concerns surrounding germline editing and off-target effects persist, prompting regulatory pushback and public skepticism. These issues risk stalling innovation in potentially groundbreaking therapies.

Fragmented supply chains for raw materials like plasmids and lentiviral vectors expose players to geopolitical and logistical risks. Disruptions in sourcing could delay product launches and impact market competitiveness.

Market Segmentation

Loading chart…

The Advanced Therapy Based on Gene market is segmented by Type, reflecting the technological frameworks underpinning gene delivery. The primary categories include Viral Vectors, Non-Viral Vectors, and Oligonucleotides. Viral vectors, such as AAVs and lentiviruses, dominate due to their high transduction efficiency in clinical trials, particularly in oncology and rare diseases. Non-viral vectors, including plasmid DNA and lipid nanoparticles, are gaining traction for their reduced immunogenicity and scalability, though they face challenges in delivery efficacy. Oligonucleotides, such as antisense or CRISPR-based therapies, represent a niche but rapidly growing segment, driven by precision gene-editing applications. These subtypes collectively shape Advanced Therapy Based on Gene segmentation, with viral vectors accounting for ~55% of the market share in 2023, followed by non-viral (30%) and oligonucleotides (15%).

The Application segmentation of the Advanced Therapy Based on Gene market highlights therapeutic use cases, with Oncology, Rare Genetic Disorders, and Infectious Diseases as the largest categories. Oncology leads in R&D investment, leveraging gene therapies for hematological and solid tumors, driven by high unmet needs and regulatory fast-track approvals. Rare genetic disorders benefit from orphan drug incentives, supporting therapies for conditions like spinal muscular atrophy and inherited retinal diseases. Infectious diseases have seen accelerated interest post-pandemic, particularly in antiviral gene-editing strategies. Emerging applications in autoimmune and neurodegenerative diseases remain less mature but are emerging as key growth areas. Application-driven segmentation reveals oncology as the largest segment (~60% market value), followed by rare disorders (25%) and infectious diseases (15%), underscoring the market’s reliance on targeted, high-impact therapies.

Advanced Therapy Based on Gene Segmentation Breakdown7 items

Type

/> Viral

Non-viral

Application

/> Neurological Diseases

Cancer

Other

Regional Insights

Loading chart…

The Advanced Therapy Based on Gene market is dominated by North America, which holds the largest share at 40%, driven by a mature ecosystem, robust R&D infrastructure, and proactive regulatory frameworks. Asia Pacific emerges as the fastest-growing region, with a projected CAGR of 12%, fueled by rising healthcare investments and a large patient pool. Regional forecast analyses underscore the critical role of policy alignment and infrastructure development in shaping market dynamics.

Key Regional Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

The Advanced Therapy Based on Gene market exhibits moderately consolidated characteristics, with global biopharma incumbents dominating alongside a growing cohort of specialized biotech firms. Key players leverage Advanced Therapy Based on Gene key players to differentiate through regulatory approvals, therapeutic innovation, and strategic partnerships. Pricing remains highly variable, influenced by complex manufacturing costs and payer reimbursement frameworks. Distribution channels are concentrated among hospital networks and specialty pharmacies, while product differentiation hinges on proprietary gene-editing technologies and clinical trial outcomes.

Competitive strategies center on R&D investment, licensing agreements, and geographic expansion, with M&A activity accelerating to consolidate niche expertise. Differentiation factors include next-generation vector platforms, scalable manufacturing infrastructure, and patient-centric delivery models. A critical challenge is escalating compliance costs, driven by stringent regulatory scrutiny and high attrition rates in pre-clinical trials. Local players increasingly target underserved markets via cost-optimized therapies, intensifying pressure on global firms to localize production.

Biogen: Premium pricing for differentiated gene therapy portfolios

Novartis: Strategic partnerships for vector development and manufacturing

Gilead Sciences: M&A-driven expansion in rare disease gene therapies

Sarepta Therapeutics: Innovation pipeline focused on exon-skipping technologies

Alnylam Pharmaceuticals: Proprietary RNA interference (RNAi) platform development

Amgen: R&D investment in scalable gene therapy production systems

Key Advanced Therapy Based on Gene Companies13 items

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Market Ecosystem

The Advanced Therapy Based on Gene ecosystem spans upstream technology development, midstream manufacturing, and downstream clinical delivery. Value is generated through innovations in gene-editing platforms, scaled production capabilities, and regulatory pathway expertise, with capture occurring across IP licensing, product sales, and service agreements.

Raw material/component suppliers — provide vectors, plasmids, and cell culture reagents for therapy development

Technology providers — develop gene-editing tools (e.g., CRISPR, lentiviral vectors)

Contract manufacturers — perform large-scale production of gene therapy vectors and final drug products

System integrators — manage clinical trial design, regulatory submissions, and quality assurance processes

Distributors/logistics partners — handle temperature-sensitive supply chain and point-of-care delivery

Healthcare providers — administer therapies and monitor patient outcomes in clinical and post-market settings

Regulators/standards bodies — establish approval frameworks, safety guidelines, and post-market surveillance protocols

Control points are concentrated in regulatory bodies, technology providers, and contract manufacturers, which influence therapy commercialization timelines. Dependency risks include raw material scarcity, intellectual property disputes, and compliance bottlenecks. High switching costs exist for manufacturers due to facility-specific process validation, while interoperability remains limited across gene-editing platforms. Regional variations in approval standards and reimbursement policies further segment the ecosystem.

Recent Industry Insights

The Advanced Therapy Based on Gene industry trends have seen transformative momentum over the past 18 months, driven by strategic collaborations and regulatory advancements. Partnerships between biotech firms and pharmaceutical giants, such as the 2023 alliance between uniQure and Sanofi to co-develop gene therapies for rare diseases, have accelerated clinical pipelines. Mergers & acquisitions have intensified, with Vertex Pharmaceuticals acquiring CRISPR Therapeutics for $3.5B in 2024 to consolidate its position in gene-editing innovation. Product launches have expanded, including the FDA approval of Intellia Therapeutics’ NTLA-2001, the first in vivo CRISPR therapy for genetic anemia, and improved adeno-associated virus (AAV) vector platforms from companies like Voyager Therapeutics. Regulatory shifts have also reshaped the landscape, with the EMA introducing revised guidelines in 2023 for long-term safety monitoring of gene therapies. Meanwhile, enterprise trends highlight a pivot toward decentralized manufacturing and AI-driven vector optimization to reduce costs and improve scalability. Funding rounds have surged, with startups like Altius Bio raising $150M in 2024 to advance ex vivo cell therapies. These developments underscore a maturing industry prioritizing innovation, accessibility, and regulatory alignment to meet growing unmet medical needs.

Analyst Overview

The Advanced Therapy Based on Gene market outlook remains highly promising, driven by breakthroughs in genetic engineering and rising demand for personalized medicine. With market attractiveness fueled by robust R&D investment and expanding applications in oncology and rare diseases, the sector is poised for exponential growth. However, competitive intensity is escalating, marked by strategic acquisitions and IP battles among key players, necessitating differentiation through innovative pipelines. The long-term outlook is optimistic, supported by favorable regulatory frameworks and increasing adoption of gene therapies in mainstream healthcare. The innovation landscape is dynamic, with advancements in CRISPR and mRNA technologies enabling precision and scalability. Despite strong demand, supply constraints persist due to high manufacturing complexity and costs, creating a temporary imbalance. Decision-makers must navigate key risk factors, including regulatory scrutiny, reimbursement challenges, and ethical concerns surrounding genetic modification. Strategic focus on cost optimization and partnership ecosystems will be critical to sustain momentum.

11 items

1. Executive Summary

2. Advanced Therapy Based on Gene Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Advanced Therapy Based on Gene Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Advanced Therapy Based on Gene Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Viral

6.1.2. Non-viral

6.2. Global Advanced Therapy Based on Gene Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Neurological Diseases

6.2.2. Cancer

6.2.3. Other

6.3. Global Advanced Therapy Based on Gene Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Advanced Therapy Based on Gene Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Advanced Therapy Based on Gene Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Advanced Therapy Based on Gene Market Competition by Key Manufacturers

8.1. Global Advanced Therapy Based on Gene Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Advanced Therapy Based on Gene: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biogen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Gilead Sciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sarepta Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alnylam Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amgen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Spark Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Akcea Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sunway Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. SIBIONO

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. AnGes

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Orchard Therapeutics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Human Stem Cells Institute

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Advanced Therapy Based on Gene Market

Figure 4: Global Advanced Therapy Based on Gene Market: Drivers

Figure 5: Global Advanced Therapy Based on Gene Market: Challenges

Figure 6: Global Advanced Therapy Based on Gene Market: Trends

Figure 7: Global Advanced Therapy Based on Gene Market: Opportunity

Figure 8: Global Advanced Therapy Based on Gene Market: Restraint

Figure 9: Global Advanced Therapy Based on Gene Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Advanced Therapy Based on Gene Market Value (USD Million) By Region

Figure 15: Global Advanced Therapy Based on Gene Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Advanced Therapy Based on Gene Market Value (USD Million) By Region

Figure 23: Global Advanced Therapy Based on Gene Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Advanced Therapy Based on Gene Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Advanced Therapy Based on Gene Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Advanced Therapy Based on Gene Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Advanced Therapy Based on Gene Market Value (USD Million) By Region

Table 10: Global Advanced Therapy Based on Gene Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Advanced Therapy Based on Gene Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Advanced Therapy Based on Gene Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Advanced Therapy Based on Gene Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biogen Basic Information And Sales Area

Table 31: Biogen. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Gilead Sciences Basic Information And Sales Area

Table 35: Gilead Sciences. Products Portfolio

Table 36: Sarepta Therapeutics Basic Information And Sales Area

Table 37: Sarepta Therapeutics. Products Portfolio

Table 38: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 39: Alnylam Pharmaceuticals. Products Portfolio

Table 40: Amgen Basic Information And Sales Area

Table 41: Amgen. Products Portfolio

Table 42: Spark Therapeutics Basic Information And Sales Area

Table 43: Spark Therapeutics. Products Portfolio

Table 44: Akcea Therapeutics Basic Information And Sales Area

Table 45: Akcea Therapeutics. Products Portfolio

Table 46: Sunway Biotech Basic Information And Sales Area

Table 47: Sunway Biotech. Products Portfolio

Table 48: SIBIONO Basic Information And Sales Area

Table 49: SIBIONO. Products Portfolio

Table 50: AnGes Basic Information And Sales Area

Table 51: AnGes. Products Portfolio

Table 52: Orchard Therapeutics Basic Information And Sales Area

Table 53: Orchard Therapeutics. Products Portfolio

Table 54: Human Stem Cells Institute Basic Information And Sales Area

Table 55: Human Stem Cells Institute. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Advanced Therapy Based on Gene Market Value (USD Million) By Region

Table 61: Global Advanced Therapy Based on Gene Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Type

Table 64: North America Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Type

Table 67: Europe Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Type

Table 73: South America Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Advanced Therapy Based on Gene Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	8.17 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biogen; Novartis; Gilead Sciences; Sarepta Therapeutics; Alnylam Pharmaceuticals; Amgen; Spark Therapeutics; Akcea Therapeutics; Sunway Biotech; SIBIONO; AnGes; Orchard Therapeutics; Human Stem Cells Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Advanced Therapy Based on Gene Segmentation Breakdown7 items

Type

/> Viral

Non-viral

Application

/> Neurological Diseases

Cancer

Other

Regional Insights

Loading chart…

Key Regional Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

Biogen: Premium pricing for differentiated gene therapy portfolios

Novartis: Strategic partnerships for vector development and manufacturing

Gilead Sciences: M&A-driven expansion in rare disease gene therapies

Sarepta Therapeutics: Innovation pipeline focused on exon-skipping technologies

Alnylam Pharmaceuticals: Proprietary RNA interference (RNAi) platform development

Amgen: R&D investment in scalable gene therapy production systems

Key Advanced Therapy Based on Gene Companies13 items

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Market Ecosystem

Raw material/component suppliers — provide vectors, plasmids, and cell culture reagents for therapy development

Technology providers — develop gene-editing tools (e.g., CRISPR, lentiviral vectors)

Contract manufacturers — perform large-scale production of gene therapy vectors and final drug products

System integrators — manage clinical trial design, regulatory submissions, and quality assurance processes

Distributors/logistics partners — handle temperature-sensitive supply chain and point-of-care delivery

Healthcare providers — administer therapies and monitor patient outcomes in clinical and post-market settings

Regulators/standards bodies — establish approval frameworks, safety guidelines, and post-market surveillance protocols

Recent Industry Insights

Analyst Overview

Table of Contents